Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Europe United Kingdom Cost Effectiveness

Takeda’ s Adcetris Wins “Landmark” Cancer Drugs Fund First In UK

  • News

Executive Summary

Takeda’s Adcetris has received expanded recommendations from England’s health technology appraisal institute, NICE, following data collected through the Cancer Drugs Fund.

You may also be interested in...



Constitutional Complaints In Germany Cast Doubt Over Fate Of UPC

The UK’s withdrawal from the EU could upset the Unitary Patent Court project.

Will COVID-19 Drive The Decline Of International Reference Pricing?

International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.

EU Orphan And Pediatric Proposals Insufficient, Says Industry

Innovators warn against slashing incentives and argue a lack of a common definition of unmet need is a stumbling block to proposals.

Table

View full table

Topics

Tags:
Europe United Kingdom Cost Effectiveness
UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By